Inbrija (Levodopa Inhalation Powder)

Inbrija (levodopa inhalation powder) is an aromatic amino acid indicated for the intermittent treatment of OFF episodes in patients with Parkinson’s disease who are treated with carbidopa/levodopa.

OFF episodes are periods of sudden, unpredictable loss or worsening of motor function (such as rigidity, tremor, bradykinesia, and motor freezing) that occur in patients with advanced Parkinson’s disease despite optimal oral carbidopa/levodopa therapy. These episodes can be disabling and significantly impact quality of life, limiting patient mobility, independence, and daily functioning.

Inbrija works by delivering levodopa directly to the lungs through inhalation, where it is rapidly absorbed through the large surface area of the respiratory epithelium. This pulmonary absorption pathway bypasses the gastrointestinal tract, providing faster onset of action compared to oral levodopa formulations. The inhaled levodopa crosses the blood-brain barrier (with the assistance of concomitant carbidopa, which is taken orally), where it is converted to dopamine by aromatic L-amino acid decarboxylase (AADC). This dopamine replenishment in the striatum and other dopaminergic brain regions rapidly reverses the motor symptoms of the OFF episode.

Inbrija is designed for patients experiencing unpredictable motor fluctuations despite optimized oral dopaminergic therapy. It is a prescription medicine and should only be used under the supervision of a qualified neurologist or Parkinson’s disease specialist.

Recommended Dosage:
The recommended dosage of Inbrija is oral inhalation of the contents of two 42 mg capsules (84 mg) as needed, up to 5 times a day. The maximum dose per OFF period is 84 mg, and the maximum daily dosage is 420 mg. Inbrija has been shown to be effective only in combination with carbidopa/levodopa

Inbrija capsules are for oral inhalation only and should be used only with the Inbrija inhaler. The capsules must not be swallowed as the intended effect will not be obtained. The capsules should be stored in their blister package and only removed immediately before use
Patients must receive proper training on the correct use of the Inbrija inhaler device from a healthcare professional before self-administration. The device should be kept clean and stored as directed. Patients should not exceed five doses per day and should maintain adequate intervals between doses.

• Levodopa can cause orthostatic hypotension, syncope, arrhythmias, and myocardial infarction, particularly in patients with cardiovascular disease or uncontrolled hypertension. Blood pressure monitoring is recommended, especially during initiation of therapy or dose adjustment.
• Inbrija is administered via inhalation and may cause airway irritation, cough, or bronchospasm in susceptible patients. Patients with chronic pulmonary disease, asthma, or chronic obstructive pulmonary disease (COPD) should use Inbrija with caution and under close medical supervision. If signs of pulmonary distress develop, discontinue use and seek medical attention.
• Levodopa use has been associated with an increased risk of melanoma in some studies. Patients should undergo regular skin examination and report any suspicious skin lesions to their dermatologist.
• Levodopa may worsen depression, anxiety, psychosis, or suicidal ideation in susceptible patients. Patients with a history of mental illness should inform their physician before starting Inbrija. Close monitoring for mood and behavioral changes is recommended.
• Levodopa may cause nausea, vomiting, or gastrointestinal bleeding. These effects may be mitigated by adequate peripheral carbidopa dosing. Patients with a history of peptic ulcer disease should use Inbrija cautiously.
• Levodopa interacts with numerous medications, including monoamine oxidase (MAO) inhibitors, certain antipsychotics, antidepressants, and antihypertensive drugs. Patients must inform their healthcare provider of all medications, supplements, and herbal products they are taking before using Inbrija.
• There are limited data on the use of Inbrija during pregnancy or breastfeeding. Women who are pregnant, planning pregnancy, or breastfeeding should discuss the potential risks and benefits with their treating neurologist before starting treatment.
• Proper use of the Inbrija inhalation device is essential for safe and effective treatment. Patients must be trained by a healthcare professional and should be monitored for correct technique at follow-up visits.

Global Approval Status:
Inbrija (levodopa inhalation powder) has received regulatory approval for the intermittent treatment of OFF episodes in patients with Parkinson’s disease who are treated with carbidopa/levodopa.

• United States: The U.S. Food and Drug Administration (FDA) approved Inbrija (levodopa inhalation powder) on December 21, 2018 for the intermittent treatment of OFF episodes in patients with Parkinson’s disease on a stable regimen of carbidopa/levodopa therapy. The approval was based on clinical efficacy demonstrated in Phase 3 clinical trials showing rapid symptom improvement during OFF episodes with a favorable safety and tolerability profile.
  Inbrija was the first and remains the only FDA-approved inhalation powder formulation of levodopa designed to rapidly treat OFF episodes in Parkinson’s disease patients, offering a novel non-invasive pulmonary delivery route that avoids gastrointestinal absorption variability.
• European Union: Inbrija (levodopa inhalation powder) has been approved in European Union member states for the treatment of Parkinson’s disease patients with motor fluctuations and OFF episodes. Regulatory approvals and availability may vary by individual country.
• Other Countries: Regulatory approval status in Canada, Australia, Japan, and other countries may vary. As of the current publicly available information, Inbrija has not yet received marketing approval in India. Patients should consult local regulatory authorities or healthcare providers regarding country-specific availability.

Approval was supported by the pivotal Phase 3 trial, which evaluated Inbrija in patients with Parkinson’s disease experiencing motor fluctuations and OFF episodes despite optimized oral carbidopa/levodopa therapy. Patients received Inbrija (42 mg levodopa inhalation powder) at the first sign of an OFF episode (up to five doses per day). The trial demonstrated that Inbrija rapidly reduced motor OFF symptoms, with symptom improvement observed within minutes of administration. The most commonly reported adverse reactions included cough, throat irritation, dysgeusia (altered taste), headache, and mild transient respiratory symptoms. The overall safety profile was favorable, with manageable side effects consistent with the known pharmacology of levodopa.
Levodopa inhalation powder was discovered and developed by Acorda Therapeutics, Inc., a biotechnology company specializing in neurology and neurodegenerative diseases.

Note: Approval and marketing status vary by country. As of the current publicly available information, Inbrija is not approved or commercially marketed in India.

What documents are required to import Inbrija to India?

Inbrija (levodopa inhalation powder) may be imported in the patient’s name only, by patients or government hospitals. The following documentation is required:

• A valid prescription from a qualified neurologist or Parkinson’s disease specialist
• The patient’s diagnostic reports (including neurological examination, imaging, and Parkinson’s disease history)
• Patient ID proof (issued by the Government of India)
• How is the order confirmed?
• The order is confirmed only after receipt and verification of a valid prescription from the neurologist and an import permit, if applicable.

Is Inbrija available in India?

Inbrija (levodopa inhalation powder) is a prescription medicine that legally requires a doctor’s prescription to be dispensed. As of the current publicly available information, Inbrija is not commercially marketed in India.

However, patients in India can legally access Inbrija through the Named Patient Program (NPP) — an import provision that allows a medicine not yet registered in India to be imported in the name of an individual patient, on the prescription of their treating physician.

Indian Pharma Network (IPN) acts as a facilitator under named patient supply, providing input on:

• Availability of Inbrija in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.) and pathways to access it
• Availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE)
• Inbrija price in India under the NPP route
• Sourcing from genuine, reliable channels in the USA, Canada, Europe, and Australia
• Ensuring full transparency throughout the process

Inbrija can be made available to patients, doctors, and hospitals in Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others— and can facilitate delivery to the patient’s treating hospital. Orders are confirmed only after receipt of a valid doctor’s prescription and an import permit, where applicable.

Indian Pharma Network (IPN) can source Inbrija from reliable channels across the world and facilitate supply to patients, doctors, and hospitals, offering worldwide access to this treatment under applicable legal provisions. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the patient’s address from New Delhi, India, after legal requirements are fulfilled.

For Inbrija cost in India and availability, contact IPN at WhatsApp: +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@indianpharmanetwork.in.

What is the generic name for the brand drug Inbrija?

Levodopa is the generic (active pharmaceutical ingredient) name for the brand drug Inbrija.

What is Inbrija used for?

Inbrija (levodopa inhalation powder) is indicated for the intermittent treatment of OFF episodes in patients with Parkinson’s disease who are treated with carbidopa/levodopa.

Who develops and manufactures Inbrija?

Inbrija was developed and is manufactured by Acorda Therapeutics, Inc., a biotechnology company focused on developing therapies for neurological conditions.

What type of medicine is Inbrija?

Inbrija is an aromatic amino acid (catecholamine precursor) delivered via pulmonary inhalation. It works by providing rapid dopaminergic stimulation to reverse OFF episodes in Parkinson’s disease.

Is Inbrija approved by the FDA?

Yes. Inbrija (levodopa inhalation powder) received FDA approval on December 28, 2018 for the intermittent treatment of OFF episodes in patients with Parkinson’s disease on a stable regimen of carbidopa/levodopa.

Where is Inbrija approved?

As of current publicly available information, Inbrija has been approved in the United States and European Union. Regulatory status in other countries may vary.

What strength and dosage form is available?

Inbrija is supplied as oral inhalation powder, 42 mg per capsule, administered using the Inbrija inhaler device.

What are the most common side effects of Inbrija?

The most commonly reported side effects are cough, nausea, upper respiratory tract infection, and sputum discolored.

How does Inbrija work differently from oral levodopa?

Inbrija delivers levodopa directly to the lungs, where it is rapidly absorbed through the respiratory epithelium. This pulmonary route of administration bypasses gastrointestinal absorption variability, providing faster onset of action (typically within minutes) compared to oral carbidopa/levodopa formulations.

How quickly does Inbrija work?

Inbrija provides rapid symptom relief, with motor improvement typically observed within minutes of administration, making it effective for treating acute OFF episodes.

Can Inbrija be used as a standalone therapy?

No. Inbrija is designed for use only in patients already on a stable regimen of oral carbidopa/levodopa therapy. It cannot replace oral Parkinson’s disease medications.

How many doses of Inbrija can I take per day?

Patients may use up to five doses of Inbrija per day, with a minimum of two hours between doses. The exact dosing frequency should be determined by the treating neurologist.

What are the storage conditions for the Inbrija device and capsules?

Inbrija capsules should be stored at room temperature, protected from moisture and light, in the original packaging. The Inbrija inhaler device should be stored as directed in the product information. Do not store in extreme temperatures.

Is training required to use the Inbrija device?

Yes. Patients must receive proper training from a healthcare professional on the correct use of the Inbrija inhaler device before self-administration. Technique should be verified at follow-up visits.

Does Inbrija interact with other Parkinson’s medications?

Inbrija (levodopa) can interact with other medications, including certain antipsychotics, antidepressants, and antihypertensive drugs. Patients must inform their neurologist of all medications they are taking.

Can Inbrija be used in patients with respiratory disease?

Patients with asthma, COPD, or chronic pulmonary disease should use Inbrija with caution and under close medical supervision, as inhalation of powder may cause airway irritation or bronchospasm.

Is Inbrija safe for elderly Parkinson’s patients?

Inbrija can be used in elderly patients; however, careful monitoring for cardiovascular and neuropsychiatric effects is recommended, as older patients may be more sensitive to levodopa’s effects.

How does Inbrija import in India work?

Inbrija import in India is possible through the Named Patient Program (NPP) — on behalf of an individual patient with a valid neurologist’s prescription. Indian Pharma Network (IPN) helps manage the process, including documentation, approvals, and delivery, so the medicine reaches the patient safely and legally.

Who is a reliable Inbrija supplier in India?

Indian Pharma Network (IPN) facilitates compliant access to Inbrija in India through global sourcing channels and structured documentation support for eligible patients, in accordance with applicable regulatory provisions.

How much does Inbrija cost in India?

Inbrija is not yet approved or marketed in India, but patients can legally access it through the Named Patient Program. Prices may vary over time due to market and regulatory factors. For the latest Inbrija cost in India, call +91 96548 60915 or WhatsApp +91 98104 69557 or email info@indianpharmanetwork.in.

Can Inbrija be accessed in SAARC countries?

Yes. In addition to Gulf countries, Inbrija can be accessed through import provisions such as the Named Patient Program in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). IPN can help facilitate compliant supply where permitted by local regulations.

Is it safe to buy Inbrija online in India?

Yes, one can buy Inbrija in India through the Indian Pharma Network (IPN), as this product is not yet registered or available in the country. IPN can help facilitate the import of Inbrija through legal channels.

Can Inbrija be delivered to my treating hospital?

Yes. IPN can facilitate delivery of Inbrija to the patient’s treating hospital across major Indian cities, under the Named Patient Program, with a valid doctor’s prescription and import permit where applicable. Leading hospitals include AIIMS Delhi, Sir Ganga Ram Hospital, Medanta – The Medicity, Apollo Hospitals Chennai, Christian Medical College (CMC), PGIMER, Kidwai Memorial Institute of Oncology, Adyar Cancer Institute, Amrita Hospital, Artemis Hospital, Safdarjung Hospital, Kauvery Hospital, Sri Ramachandra Medical Centre, Cytecare Cancer Hospital, MIOT International, SCTIMST, NIMS Hospital, KIMS Hospitals, AIG Hospitals, Bombay Hospital, Lilavati Hospital, Care Hospitals, Narayana Health City, Jaslok Hospital, Yashoda Hospitals, Fortis Memorial Research Institute, Kokilaben Dhirubhai Ambani Hospital, P. D. Hinduja Hospital, Manipal Hospitals, Aster Medcity, Indraprastha Apollo Hospital, King George’s Medical University (KGMU), Shalby Hospitals, Tata Memorial Centre, HCG Cancer Center, Basavatarakam Indo-American Cancer Hospital, Cancer Institute (WIA), Max Healthcare, and Rajiv Gandhi Cancer Institute & Research Centre.

What are the storage conditions for Inbrija?

Inbrija capsules should be stored at room temperature (approximately 20–25°C / 68–77°F), protected from moisture and light, in the original packaging. Do not freeze or refrigerate. The Inbrija inhaler device should be kept clean and stored as directed in the product instructions.